800 1222·2022 ANNI

UNIVERSITÀ DEGLI STUDI DI PADOVA

Laboratorio di ricerca bibliografica per gli studenti di farmacia

secondo modulo

SBA SISTEMA BIBLIOTECARIO DI ATENEO

POLO DI SCIENZE

Le banche dati per le Scienze del Farmaco

pch.vector - it.freepik.com

Tra le risorse più importanti e utili che l'Ateneo mette a disposizione per la ricerca scientifica troviamo le banche dati.
Le banche dati si possono occupare di una o più aree disciplinari e soprattutto forniscono informazioni bibliografiche e fattuali.

Come trovarle? Utilizzando GalileoDiscovery!

https://galileodiscovery.unipd.it/discovery/search?vid=39UPD_INST:VU1



Posso fare una ricerca per Categoria > selezionando Scienze del Farmaco trovo in elenco ben 21 banche dati specifiche

Piccola guida alle principali e più utilizzate banche dati per le scienze del farmaco

Banche dati di varie tipologie: bibliografiche, citazionali e banche dati fattuali

- SCOPUS
- PUBMED
- INFORMATORE FARMACEUTICO (codifa)
- MICROMEDEX
- WEB OF SCIENCE
- PUBCHEM
- ADISINSIGHT
- MEDICAMENTA e European Pharmacopoeia

Pubmed

Tra le più importanti banche dati bibliografiche a livello internazionale.
E' una risorsa gratuita per la ricerca e il recupero di riferimenti bibliografici ad articoli scientifici e ad altri documenti di ambito biomedico e biologico.

https://pubmed.ncbi.nlm.nih.gov/?otool=iitudplib

SCOPUS

Banca dati bibliografica e citazionale di ambito multidisciplinare a pagamento.

Al suo interno troviamo dati bibliografici (titolo, abstract…) di articoli, atti di convegno…

Accessibile dalle sedi universitarie e da casa via Auth Proxy o SSO

https://www.scopus.com/search/form.uri?display=basic#basic


Scopus
Search
Sources
Lists
SciVal
Create account
Sign in
Start exploring
Discover the most reliable, relevant, up-to-date research. All in one place.
Brought to you by
University of Padua, Library+shibboleth
Documents
Authors
Affiliations
Search tips
Search within
Article title, Abstract, Keywords
Search documents *
Add search field
Add date range
Advanced document search
Search


17,208 document results
TITLE-ABS-KEY (covid AND vaccine)
Edit
Save
Set alert
Search within results...
Refine results
Limit to
Exclude
Open Access
All Open Access (14,306)
Gold (5,593)
Hybrid Gold (1,299)
Bronze (5,783)
Green (10,550)
Learn more
Year
2022 (53)
2021 (12,379)
2020 (4,771)
2019 (4)
2007 (1)
Documents
Secondary documents
Patents
View Mendeley Data (3748)
Analyze search results
Show all abstracts
Sort on: Cited by (highest)
All
Export
Download
View citation overview
View cited by
Add to List
Document title
Authors
Year
Source
Cited by
1 Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
Open Access
Polack, F.P., Thomas, S.J., Kitchin, N., (...), Jansen, K.U., Gruber, W.C.
2020
New England Journal of Medicine
383(27), pp. 2603-2615
2393
View abstract
Cerca con Galileo
View at Publisher
Related documents
2 Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
Open Access
Baden, L.R., El Sahly, H.M., Essink, B., (...), Miller, J., Zaks, T.
2021
New England Journal of Medicine
384(5), pp. 403-416
1487
View abstract
Cerca con Galileo
View at Publisher
Related documents
3 A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Open Access
Gordon, D.E., Jang, G.M., Bouhaddou, M., (...), Shoichet, B.K., Krogan, N.J.
2020
Nature
583(7816), pp. 459-468
1338
View abstract
Cerca con Galileo
View at Publisher
Related documents

Document type
Article • Bronze Open Access • Green Open Access

Source type
Journal

ISSN
00284793

DOI
10.1056/NEJMoa2034577

View more

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Polack F.P.[a], Thomas S.J.[c], Kitchin N.[a], Absalon J.[d], Gurtman A.[d], Lockhart S.[a], Perez J.L.[f], Marc G.P.[b], Moreira E.D.[h], Zerbini C.[i], Bailey R.[a], Swanson K.A.[d]

Show additional authors | Save all to author list

[a] Fundacion INFANT, Buenos Aires, Argentina
[b] ITrials-Hospital Militar Central, Buenos Aires, Argentina
[c] State University of New York, Upstate Medical University, Syracuse, NY, United States
[d] Vaccine Research and Development, Pfizer, Pearl River, NY, United States

View additional affiliations

2.584 Citations in Scopus | 383 Views count | View all metrics

Full text options

Abstract
Indexed keywords
Drug tradenames
SciVal Topics
Chemicals and CAS Registry Numbers
Metrics
Funding details

Abstract

BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 fulllength spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS A total of 43, 548 participants underwent randomization, of whom 43, 448 received injections: 21, 720 with BNT162b2 and 21, 728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9

(2022) Food Control

The behavioral immune system and vaccination intentions during the coronavirus pandemic
Karlsson, L.C. , Soveri, A. , Lewandowsky, S.
(2022) Personality and Individual Differences

Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2
Wang, Y.-T. , Long, X.-Y. , Ding, X.
(2022) European Journal of Medicinal Chemistry

View all 2584 citing documents

Inform me when this document is cited in Scopus:

Set citation alert >

Related documents

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mulligan, M.J. , Lyke, K.E. , Kitchin, N.
(2020) Nature

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
Li, J. , Hui, A. , Zhang, X.
(2021) Nature Medicine

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
Xie, X. , Liu, Y. , Liu, J.
(2021) Nature Medicine

View all related documents based on references

Find more related documents in Scopus based on:

Web Of Science (WOS)

Altra importante banca dati bibliografica e citazionale di ambito multidisciplinare

a pagamento dove ricercare la letteratura scientifica.

Accessibile dalle sedi universitarie e da casa solo via Auth Proxy

Web of Science™

https://www.webofscience.com/wos/woscc/basic-search


Clarivate
English
Products
Web of Science™
Search
Marked List
History
Alerts
Sign In
Register
Discover multidisciplinary content
from the world's most trusted global citation database.
Search in: Web of Science Core Collection
Editions: All
DOCUMENTS
AUTHORS
CITED REFERENCES
STRUCTURE
All Fields
Example: liver disease india singh
Add row
Add date range
Advanced Search
Clear
Search
CRUI - Universita degli Studi di Padova
Clarivate
31


Publications
You may also like...
Refine results
Search within results for...
Quick Filters
Highly Cited Papers 42
Review Articles 1,296
Early Access 120
Open Access 6,531
Associated Data 48
Publication Years
2022 2
2021 1,006
2020 1,263
2019 1,205
2018 1,049
See all >
Document Types
Articles 16,714
Meeting Abstracts 1,449
Review Articles 1,296
Proceedings Papers 1,022
Letters 724
0/21,015
Add To Marked List
Export
Relevance
1 of 421
1 A review: Fentanyl and non-pharmaceutical fentanyls
Suzuki, J and El-Haddad, S
Feb 1 2017 | DRUG AND ALCOHOL DEPENDENCE 171 , pp.107-116
Background: Fentanyl and non-pharmaceutical fentanyls (NPFs) have been responsible for numerous outbreaks of overdoses all over the United States since the 1970s. However, there has been a growing concern in recent years that NPFs are contributing to an alarming rise in the number of opioid-related overdoses. ... Show more
Full Text at Publisher
189 Citations
164 References
Related records
2 An optimized method for sample collection, extraction, and analysis of fentanyl and fentanyl analogs from a non-porous surface
Ciesielski, AL; Wagner, JR; (...); Snawder, J
Jun 1 2021 | TALANTA 228
Illicit use of the potent opioid fentanyl and its analogs (fentanyls) are on the rise in the United States. As use increases, drug production tends to also increase, leading to more locations being contaminated with the potentially lethal substance. Because fentanyl-contaminated locations may present a risk to the general public, a method for sampling, ide ... Show more
View full text
29 References
Related records
3 Fentanyl and fentanyl-analog involvement in drug-related deaths
Dai, Z; Abate, MA; (...); Mock, AR
Mar 1 2019 | DRUG AND ALCOHOL DEPENDENCE 196 , pp.1-8
Background: To describe and analyze the involvement of fentanyl and fentanyl analogs (FAs) in drug-related deaths in West Virginia (WV), United States.
Methods: Retrospective analyses of all WV drug-related deaths from 2005 to 2017 were performed, inc ... Show more
Free Accepted Article From Repository
Full Text at Publisher
21 Citations
38 References
Related records

Document Delivery (DD)

L'articolo che state cercando non è disponibile a Padova?
Ci pensiamo noi a recuperarlo con il servizio di fornitura documenti!



Per informazioni sul servizio:
http://bibliotecascienzefarmaco.cab.unipd.it/usa-la-biblioteca/contenuti-usa-la-biblioteca/document-delivery

Pubchem

Pubchem è una banca dati fattuale,gratuita di ambito chimico.
Si trovano informazioni su strutture chimiche, identificatori, proprietà chimiche e fisiche, attività biologiche, brevetti, dati su salute, sicurezza, tossicità etc.

https://pubchem.ncbi.nlm.nih.gov/



COMPOUND SUMMARY

Aspirin

PubChem CID	2244
Structure	2D 3D Crystal Find Similar Structures
Chemical Safety	Irritant Laboratory Chemical Safety Summary (LCSS) Datasheet
Molecular Formula	$C_9H_8O_4$ or $CH_3COOC_6H_4COOH$ or $HC_9H_7O_4$
Synonyms	aspirin ACETYLSALICYLIC ACID 50-78-2 2-Acetoxybenzoic acid 2-(Acetyloxy)benzoic acid More...
Molecular Weight	180.16
Dates	Modify 2021-10-16 Create 2004-09-16

Aspirin or acetylsalicylic acid is perhaps the most commonly used analgesic and antipyretic medication worldwide, having been in clinical use for over 100 years. Aspirin can cause several forms of liver injury; in high doses, aspirin can cause moderate to marked serum aminotransferase elevations occasionally with jaundice or signs of liver dysfunction, and in lower doses in susceptible children with a febrile illness aspirin can lead to Reye syndrome.

LiverTox

Aspirin is an orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.

NCI Thesaurus (NCIt)

Also known as *Aspirin*, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI). Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer. Aspirin is classified as a *non-selective cyclooxygenase (COX) inhibitor* and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others. Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants.

DrugBank

Cite Download

CONTENTS

- Title and Summary
- 1 Structures
- 2 Names and Identifiers
- 3 Chemical and Physical Properties
- 4 Spectral Information
- 5 Related Records
- 6 Chemical Vendors
- 7 Drug and Medication Information
- 8 Pharmacology and Biochemistry
- 9 Use and Manufacturing
- 10 Identification
- 11 Safety and Hazards
- 12 Toxicity
- 13 Associated Disorders and Diseases
- 14 Literature
- 15 Patents
- 16 Biomolecular Interactions and Pathways
- 17 Biological Test Results



PubChem Aspirin (Compound)

Odorless, colorless to white, crystalline powder; [aspirin] [Note: Develops the vinegar-like odor of acetic acid on contact with moisture.]

The National Institute for Occupational Safety and Health (NIOSH)

Cite Download

CONTENTS

- Title and Summary
- 1 Structures
- 2 Names and Identifiers
- 3 Chemical and Physical Properties
- 4 Spectral Information
- 5 Related Records
- 6 Chemical Vendors
- 7 Drug and Medication Information
- 8 Pharmacology and Biochemistry
- 9 Use and Manufacturing
- 10 Identification
- 11 Safety and Hazards
- 12 Toxicity
- 13 Associated Disorders and Diseases
- 14 Literature
- 15 Patents
- 16 Biomolecular Interactions and Pathways
- 17 Biological Test Results
- 18 Classification

3.2.2 Color/Form

Monoclinic tablets or needle-like crystals

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc., 2006, p. 140

Hazardous Substances Data Bank (HSDB)

Colorless to white, crystalline powder.

NIOSH. NIOSH Pocket Guide to Chemical Hazards & Other Databases CD-ROM. Department of Health & Human Services, Centers for Disease Prevention & Control, National Institute for Occupational Safety & Health. DHHS (NIOSH) Publication No. 2005-151 (2005)

Hazardous Substances Data Bank (HSDB)

3.2.3 Odor

Odorless, but in moist air it is gradually hydrolyzed and acquires odor of acetic acid

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc., 2006, p. 140

Hazardous Substances Data Bank (HSDB)

Odorless [Note: Develops the vinegar-like odor of acetic acid on contact with moisture].

NIOSH. NIOSH Pocket Guide to Chemical Hazards & Other Databases CD-ROM. Department of Health & Human Services, Centers for Disease Prevention & Control, National Institute for Occupational Safety & Health. DHHS (NIOSH) Publication No. 2005-151 (2005)

Hazardous Substances Data Bank (HSDB)

3.2.4 Boiling Point

Informatore farmaceutico (Codifa)

È il motore di ricerca per tutti i prodotti medicinali, salutistici e veterinari commercializzati in Italia.

Accessibile dalle sedi universitarie e da casa solo via Auth Proxy

(Attenzione 2 accessi simultanei)

https://www.codifa.it



E' possibile visualizzare gli RCP dei farmaci, le precauzioni da valutare e le interazioni.
Le informazioni riportate sono aggiornate in tempo reale attraverso i contatti diretti con le aziende farmaceutiche e parafarmaceutiche e l'utilizzo di fonti ufficiali quali AIFA, EMA, Gazzetta Ufficiale e Ministero della Salute.

ASPIRINA

Bayer S.p.A.
325 mg 10 compresse

Ultimo aggiornamento il: 20/07/2021

Stampa

Precauzioni da valutare

I simboli sono da interpretarsi come segnalazione di precauzione nell'uso, di valutazione del prodotto e dell'eventuale rapporto rischio beneficio

N° INTERAZIONI TOTALI:276

17 Interazione clinicamente rilevante

136 Interazione rilevante gestibile con aggiustamento del dosaggio

AIC	004763254
TITOLARE	Bayer S.p.A.
CLASSE	C
RICETTA	OTC - medicinale di automedicazione
ATC	N02BA01 - Acido acetilsalicilico
PRINCIPIO ATTIVO	acido acetilsalicilico
GRUPPO TERAP.	Antiaggreganti piastrinici, Antipiretici, Analgesici FANS
PREZZO	€ 6,3
FORMA FARMACEUTICA	compressa
PIANO TERAPEUTICO	No
PHT	No

RCP

- 1 - DENOMINAZIONE DEL MEDICINALE
- 2 - COMPOSIZIONE QUALITATIVA E QUANTITATIVA
- 3 - FORMA FARMACEUTICA
- 4 - INFORMAZIONI CLINICHE
- 4.1 - Indicazioni terapeutiche
- 4.2 - Posologia e modo di somministrazione
- 4.3 - Controindicazioni
- 4.4 - Avvertenze speciali e precauzioni d'impiego
- 4.5 - Interazioni con altri medicinali ed altre forme d'interazione
- 4.6 - Fertilità, gravidanza e allattamento
- 4.7 - Effetti sulla capacità di guidare veicoli e sull'uso di macchinari
- 4.8 - Effetti indesiderati
- 4.9 - Sovradosaggio
- 5 - PROPRIETA' FARMACOLOGICHE
- 5.1 - Proprietà farmacodinamiche
- 5.2 - Proprietà farmacocinetiche
- 5.3 - Dati preclinici di sicurezza
- 6 - INFORMAZIONI FARMACEUTICHE
- 6.1 - Elenco degli eccipienti
- 6.2 - Incompatibilità
- 6.3 - Periodo di validità
- 6.4 - Precauzioni particolari per la conservazione
- 6.5 - Natura e contenuto del contenitore
- 6.6 - Precauzioni particolari per lo smaltimento e la manipolazione
- 7 - TITOLARE DELL'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO
- 8 - NUMERO(I) DELL'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO
- 9 - DATA DELLA PRIMA AUTORIZZAZIONE/RINNOVO DELL'AUTORIZZAZIONE
- 10 - DATA DI REVISIONE DEL TESTO
- 11 DOSIMETRIA
- 12 ISTRUZIONI PER LA PREPARAZIONE DI RADIOFARMACI

Micromedex

È un insieme di database in lingua inglese contenenti informazioni evidence-based su farmaci e le loro interazioni, tossicologia, analisi di laboratorio e medicina alternativa.

Disponibile solo dalla sottorete della biblioteca e del dipartimento di scienze del farmaco.

IBM Micromedex®

https://www.micromedexsolutions.com/micromedex2/librarian/



IBM Micromedex®

Il Mio Abbonamento | Gateway | Training Center | Guida | Centro per il download | Esci

aspirin

Pagina iniziale | Interazioni dei farmaci | Compatibilità EV | Identificazione farmaci | Confronto farmaci | NeoFax® / Pediatrics | Ricerca farmaci e dati tossicologici | Calcolatori

Aspirin

Drug Classes: Analgesic | Antipyretic | All

Routes: Oral | Rectal

Regulatory Authority: FDA

Risposte rapide | Risposte approfondite | Tutti i risultati

Dosing/Administration
- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety
- Contraindications
- Precautions

Dosing/Administration

Adult Dosing

Stampa

Vedere 'Risposte approfondite' per i risultati dettagliati.

Important Note

- Beers Criteria: Use caution or avoid use as potentially inappropriate in older adults [1].
- Orphan drug designation: Treatment of Kawasaki Disease

Antiphospholipid syndrome

- Primary prophylaxis in antiphospholipid antibody (aPL)-positive persons: 75 to 100 mg orally daily (guideline dosage) [2]
- Pregnant women with a high-risk aPL profile but no history of thrombosis or pregnancy complications (with or without SLE): 75 to 100 mg orally daily (guideline dosage) [2]
- Obstetric antiphospholipid syndrome: 75 to 100 mg orally daily in combination with heparin (guideline dosage) [2]

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

Risultati correlati
- Malattia
- Medicina alternativa
- Tossicologia

- Drug Consults
- Martindale
- PDR®
- Product Lookup - Martindale
- Product Lookup - Tox & Drug

AdisInsight

Banca dati a pagamento che raccoglie dati su farmaci in sviluppo a livello globale, relativi a studi clinici e a casi di reazioni avverse ai farmaci. Presenta il panorama completo a partire dagli stadi precoci di ricerca fino allo sviluppo clinico e agli aspetti di safety successivamente osservati dalla messa in commercio.

Accessibile dalle sedi universitarie e da casa solo via Auth Proxy

https://adisinsight.springer.com/

At a glance

Originator	Amgen
Developer	Amgen; Indiana University; Novartis; Rigshospitalet
Class	Antimigraines; Monoclonal antibodies
Mechanism of Action	Calcitonin gene-related peptide receptor antagonists
Orphan Drug Status	No
New Molecular Entity	Yes

Highest Development Phases

Marketed	Migraine
Phase II	Headache; Rosacea; Temporomandibular joint dysfunction syndrome; Trigeminal neuralgia
Discontinued	Hot flashes

Most Recent Events

02 Nov 2021	Phase-II clinical trials in Temporomandibular joint dysfunction syndrome (In adults) in USA (SC) (NCT04884763)
31 Oct 2021	Dansk Hovedpine Center completes its phase II clinical trials in Trigeminal neuralgia in Denmark (unspecified route) (NCT04054024)
28 Jun 2021	No recent reports of development identified for phase-I development in Migraine(In adolescents, In children) in USA

Table of Contents

Back to top

banca dati	ambito disciplinare	citazionale e bibliografica	fattuale	a pagamento	gratuita
Scopus	multidisciplinare	x		x	
Web of Science	multidisciplinare	x		x	
Pubmed	biomedico	bibliografica			x
Pubchem	chimico		x		x
Codifa	farmaceutico		x	x	
Micromedex	farmaceutico		x	x	
AdisInsight	farmaceutico		x	x	

Materiali ulteriori disponibili in biblioteca: repertori

MEDICAMENTA

È una fonte di informazione esauriente e in lingua italiana sui principi attivi e su ogni molecola impiegata in terapia: denominazione, caratteristiche chimico-fisiche, saggi di identificazione e purezza, tossicità, controindicazioni...

Formato cartaceo (versione online con pw accesso dalla biblioteca e dai laboratori)

MEDICAMENTA

http://www.medicamenta.com/it

EUROPEAN PHARMACOPOEIA

È il codice farmaceutico che armonizza i testi delle principali farmacopee ufficiali degli Stati Europei e individua norme comuni riconosciute sulla qualità dei medicinali.

Complesso di disposizioni tecnico/scientifiche ed amministrative, per il controllo della qualità dei medicamenti, delle sostanze e/o dei preparati finali, mediante l'indicazione di metodi di verifica chimico analitici e tecnologici delle specifiche di qualità, dei metodi di preparazione o della formulazione.

In formato cartaceo ma anche online con pw (solo per docenti e laureandi..)

https://pheur.edqm.eu/home

Cosa cerco e dove lo trovo

Tipo di ricerca	Dove cercare
Sostanza	Pubchem, Medicamenta, European Pharmacopoeia, Farmacopea italiana
Farmaco	Codifa, Medicamenta, Micromedex,AdisInsight
Tossicità ed effetti collaterali	Codifa, Micromedex, Pubchem
Farmacodinamica/cinetica	Pubmed, Micromedex, Codifa
Studi clinici	Pubmed, AdisInsight
Interazioni farmacologiche	Codifa, Micromedex, Pubmed
letteratura scientifica	Pubmed, Scopus e WOS

...e queste sono solo le principali, ce ne sono ancora molte altre.
Se hai bisogno chiedi aiuto in biblioteca!

pch.vector-freepik.com